A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
-
Student nurse placements in primary health care
With an urgent need to manage increasing rates of chronic disease, an ageing population, and a rapidly-ageing primary health care nurse workforce, Australia desperately needs more primary health care nurses to enter the workforce before the current generation retires and cannot pass on its skills.
Most nurses start their career in a hospital. Historically, it was difficult for universities and tertiary education providers to arrange placements for student nurses in primary health care. However, the APNA Student Nurse Placement Program provides student nurses with a foot in the door to a career in vibrant primary health care settings such as general practice or community health to perform supervised activities.
-
“Nurses can do more, should do more and now they will do more”, The Hon Minister Greg Hunt MP, Minister for Health.
Advanced Practice Nurses comprise 9% of the total nursing workforce, with 26,000 clinicians Australia wide. However although highly skilled, they are under-utilised and constrained to the full scope of practice. The Australian College of Nursing believes this needs to change. Nurse led models of care in which Advanced Practice Nurses play a significant role in service provision, must feature in the future. ACN President Professor Christine Duffield FACN states, “It’s now widely acknowledged internationally that nurses can provide a clinical and very valuable service that’s better suited to the healthcare needs of some consumer groups.”
